Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
341.12
-25.73 (-7.01%)
At close: Jul 31, 2026, 4:00 PM EDT
340.00
-1.12 (-0.33%)
After-hours: Jul 31, 2026, 7:40 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Krystal Biotech stock has a consensus rating of "Strong Buy" and an average price target of $376.75. The average 1-year stock price forecast is 10.45% higher than the current stock price, while the lowest is $284 (-16.74%) and the highest is $474 (+38.95%).
Price Target: $376.75 (+10.45%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 22, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $364 → $396 | Buy | Maintains | $364 → $396 | +16.09% | Jul 14, 2026 |
| Jefferies | Jefferies | Buy Reiterates $474 | Buy | Reiterates | $474 | +38.95% | Jul 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $306 → $403 | Buy | Maintains | $306 → $403 | +18.14% | Jun 18, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $310 → $361 | Buy | Reiterates | $310 → $361 | +5.83% | Jun 16, 2026 |
Financial Forecast
Revenue This Year
516.05M
from 389.13M
Increased by 32.62%
Revenue Next Year
670.25M
from 516.05M
Increased by 29.88%
EPS This Year
8.21
from 6.84
Increased by 19.97%
EPS Next Year
9.87
from 8.21
Increased by 20.30%
EPS and Forward PE are based on non-GAAP adjusted numbers.